BioDelivery Sciences International, Inc. (BDSI) Receives Average Recommendation of “Buy” from Brokerages

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has earned an average rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $4.50.

Several research firms have recently commented on BDSI. HC Wainwright set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, October 13th. Roth Capital set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday, October 12th. Cantor Fitzgerald set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday, October 12th. Finally, Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Sunday, October 22nd.

Shares of BioDelivery Sciences International (BDSI) opened at $2.60 on Tuesday. The company has a market cap of $145.30, a P/E ratio of 28.89 and a beta of 0.74. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International has a 12-month low of $1.55 and a 12-month high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The business’s revenue for the quarter was up 215.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.30) EPS. analysts forecast that BioDelivery Sciences International will post 0.16 earnings per share for the current year.

In related news, Director Mark A. Sirgo sold 108,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $2.57, for a total value of $277,560.00. Following the completion of the sale, the director now owns 1,759,262 shares in the company, valued at approximately $4,521,303.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Sirgo sold 162,509 shares of BioDelivery Sciences International stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $2.78, for a total transaction of $451,775.02. Following the completion of the sale, the director now owns 1,759,262 shares of the company’s stock, valued at approximately $4,890,748.36. The disclosure for this sale can be found here. Insiders sold a total of 980,011 shares of company stock valued at $2,666,275 in the last quarter. 7.73% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of BDSI. Royce & Associates LP acquired a new stake in BioDelivery Sciences International in the 3rd quarter valued at approximately $3,814,000. Stonepine Capital Management LLC increased its holdings in BioDelivery Sciences International by 22.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after purchasing an additional 632,853 shares during the last quarter. EAM Investors LLC acquired a new position in shares of BioDelivery Sciences International in the second quarter worth $1,348,000. GSA Capital Partners LLP grew its stake in shares of BioDelivery Sciences International by 10.1% in the second quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock worth $1,369,000 after acquiring an additional 44,700 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of BioDelivery Sciences International in the third quarter worth $116,000. Hedge funds and other institutional investors own 44.25% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/23/biodelivery-sciences-international-inc-bdsi-receives-average-recommendation-of-buy-from-brokerages.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply